Oakdale Strategy Group’s Jennifer Fry summed up the situation, stating, “Before our client can do a valuation on Amgen, she needs a credible, realistic forecast for denosumab. Analysts are projecting this to be $2 billion, or even $5 billion in revenue, but I’m pretty skeptical about analyst forecasts. We need to create a credible forecast for denosumab’s U.S. revenue in 2015.”